1. China Stocks

  2. •

    Electronic technology

  3. •

    Electronic equipment/Instruments
Rainmed Medical Limited

Rainmed Medical Limited

HHKEX:2297
0.15
HKD
+0.00
(-1.29%)
199.69MMarket Cap
Rainmed Medical Limited
HKEX:2297
(Hong Kong Exchange)

Recent

price

0.15

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
TTM
CNY
0.01
0.07
0.09
0.06
0.03
0.01
- -
Revenue per Share
-0.12
-0.54
-1.5
-0.1
-0.1
-0.06
- -
Basic EPS, GAAP
- -
-0.09
-0.16
-0.2
-0.12
-0.06
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.2
-0.67
0.53
0.44
0.35
0.26
0.35
Book Value per Share
-0.2
-0.67
0.52
0.39
0.31
0.23
0.31
Tangible Book Value per Share
1,167
1,167
898
1,168
1,168
1,292
1,168
Basic Weighted Avg Shares
6
81
84
73
40
19
- -
Sales/Revenue/Turnover
-549.04
-175.89
-173.54
-181.31
-251.05
-389.66
- -
Operating Margin (%)
2
11
17
22
23
20
- -
Depreciation Expense
-145
-634
-1,346
-116
-113
-77
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-2,382.16
-780.36
-1,609.93
-158.2
-284.99
-401.98
- -
Profit Margin (%)
-15
532
535
328
190
24
190
Working Capital
11
9
4
12
5
4
5
LT Debt
-221
-774
619
520
410
358
410
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-20.43
-24.62
-20.17
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
ST Debt
8
23
21
LT Borrowings
12
8
4
LT Finance Leases
- -
4
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,168
1,168
1,168
Market Capitalization
456
201
188

Working Capital

CNY

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
Total Current Assets
369
324
238
Cash, Cash Equivalents & STI
335
288
206
Accounts Receivable, Net
10
8
2
Inventories
10
11
11
Total Current Liabilities
41
109
48
Payables & Accruals
- -
- -
- -
ST Debt
8
23
21
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
4.18%
-12.67%
Free Cash Flow
- -
1,162.58%
-41%
Net Income, GAAP
- -
64.64%
-32.08%
Sales/Revenue/Turnover
- -
224.97%
-51.85%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
73
2024
- -
- -
40
2025
- -
- -
19

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.1
2024
- -
- -
-0.1
2025
- -
- -
-0.06

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
Advantest Corp. (TSE:6857)
Unusual Machines, Inc. (AMEX:UMAC)
FuelCell Energy, Inc. (NASDAQ:FCEL)
Lasertec Corp. (TSE:6920)
Hitachi Energy India Limited (NSE:POWERINDIA)
Keysight Technologies Inc. (NYSE:KEYS)
Business
Rainmed Medical Limited (2297.HK) develops and commercializes vascular interventional surgical robotics and precision diagnostic systems for coronary artery disease assessment. Founded in 2014 and headquartered in Suzhou, Jiangsu Province, China, the company offers core products including the caFFR System, comprising FlashAngio caFFR System and FlashPressure caFFR pressure transducer for less-invasive physiological assessment of coronary ischemia severity; the caIMR System, including FlashAngio caIMR System and FlashPressure caIMR pressure transducer for microcirculatory resistance measurement; and in vitro diagnostic (IVD) reagents covering liver function, kidney function, blood lipids, myocardial function, coagulation and peptide categories through subsidiary Tianjin Yuehekang Biotechnology Co., Ltd.; it also advances pipeline products such as FlashBot vascular interventional surgery robot, intelligent angiographic injection system and Flash RDN system. The company operates primarily in China across over 700 hospitals with international commercialization in Europe, Australia, Japan and South Korea. In March 2023, Rainmed acquired a 68.32% stake in Tianjin Yuehekang for RMB25.96 million to expand its precision diagnostic portfolio from perioperative coverage to admission and bedside testing; the caIMR System received NMPA approval in April 2023 as the world's first less-invasive IMR product post-confirmatory trial; caFFR and caIMR were included in China's Expert Consensus on Coronary Physiological Assessment in December 2022; and in May 2023, the company purchased 20,000 sq.m. land in Suzhou for integrated manufacturing and R&D facilities.